Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.
Pelvic gynecological malignancies account for 6% of all cancers. In the relapsed state, classical treatments are limited. There is an urgent need for new and personalized treatment. Wilms' tumor gene 1 (WT1) is the most important tumor-associated antigen. Although highly present in gynecological tumors, active immunotherapy against it is still underexplored. This review gives an insight into the importance of WT1 in pelvic gynecological malignancies and the first taken steps into the world of WT1 immunotherapy.
Department of Oncology, KU Leuven, Laboratory of Pediatric Immunology, Onderwijs and Navorsing 1, Herestraat 49, box 811, 3000 Leuven, Belgium.
A
A
Coosemans
I
I
Vergote
S W
SW
Van Gool
D000951:Antigens, Neoplasm / Q000276:immunology*; D005260:Female; D005833:Genital Neoplasms, Female / Q000276:immunology / Q000473:pathology / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D010386:Pelvic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy; D025721:WT1 Proteins / Q000276:immunology*
D000951:Antigens, Neoplasm; D025721:WT1 Proteins; C583751:WT1 protein, human
DC; WT1; Wilms' tumor gene 1; dendritic cell; immunotherapy; ovarian cancer; uterine cancer